На главную
Результаты поиска “Activus pharma generic drug”
Actavis - think smart medicine
 
00:31
Actavis Group is one of the world's leading players in first-class generic pharmaceuticals and the new name in hospital pharmaceuticals.
Просмотров: 1813 ActavisTV
Actavis Takes 'Codeine Syrup' Off Market Due to Rappers Turning Feigns!
 
06:27
DJ Akademiks speaks on the company 'Actavis' taking off 'Codeine Syrup' off the market due to its abuse by Rappers and urban youth who have glamorized and abused its use. Join our community on FB http://www.facebook.com/iamakademiks
Просмотров: 113308 DJ Akademiks
FTC v. Actavis Inc.: Oral Argument - March 25, 2013
 
01:01:19
Facts: In 2000, Solvay Pharmaceuticals successfully patented AndroGel, a topical gel medication. Shortly after the FDA approved the medication, generic drug manufacturers Watson Pharmaceuticals and Paddock Laboratories began developing generic versions of the gel. Solvay filed a patent infringement suit against Watson and Paddock, but the manufacturers counter-claimed that Solvay's patent was invalid to begin with. As the infringement suit progressed, Solvay feared that it would lose its monopoly on AndroGel. To prevent this, Solvay entered into a reverse payment agreement with the two manufacturers. In return for dropping the suit and maintaining exclusivity, Solvay agreed to pay the manufacturers a sizeable fee. The agreement allowed Solvay to maintain its monopoly, despite the possible invalidity of the patent, in exchange for sharing some of the profits with its potential competitors. Shortly after entering the agreement, the Federal Trade Commission ("FTC") filed a complaint against the pharmaceutical companies. The FTC claimed that Solvay was unlikely to win the patent infringement suit; therefore the settlement unfairly protected an invalid patent monopoly. By limiting competition in the AndroGel market, the manufacturers were restraining trade in violation of antitrust laws. The manufacturers argued that the FTC failed to state a valid claim because the agreement merely protected Solvay's already existing patent rights. The United States District Court for the Northern District of Georgia agreed with the manufacturers and dismissed the case. The FTC appealed to the United States Court of Appeals for the Eleventh Circuit, which affirmed the lower court's decision. The appellate court explained that the manufacturers' reverse payment settlement is lawful as long as it restrains competition in the same way that patent protection typically restrains competition. Question: Are reverse payment agreements per se lawful, rather than presumptively anticompetitive? Conclusion: No. Justice Stephen G. Breyer delivered the opinion for the 5-3 majority. The Court held that reverse payment settlements are not presumptively unlawful and that the FTC's lawsuit should have been allowed to proceed. Although patent-based settlement agreements can sometimes violate anti-trust laws, the Court declined to apply an all-or-nothing rule regarding these agreements. Instead, the Court stated that there are five considerations that should have allowed the consideration of FTC's case. These considerations are: 1) that specific restraints in the settlement agreement had the potential to adversely effect competition; 2) that certain anti-trust consequences will sometimes prove unjustified; 3) that if a reverse payment settlement can cause anticompetitive harm, the patent-holder likely has the power to bring about that harm as well; 4) an anti-trust claim may be more administratively feasible than the lower court believed; and 5) the fact that a large, unjustified reverse payment settlement risks anti-trust liability does not prevent litigating parties from settling their lawsuits. The Court held that these considerations outweighed the lower court's decision to provide anti-trust immunity to reverse payment settlements. Chief Justice John Roberts wrote a dissent in which he argued that the majority's decision discourages generic pharmaceutical companies from challenging patents because it eliminates the possibility of meaningful settlements. He argued that this decision instead forces generic companies into costly litigation that could be more efficiently handled through settlement negotiations. Justice Antonin Scalia and Justice Clarence Thomas joined in the dissent. For more information about this case see: https://www.oyez.org/cases/2012/12-416 Section 1: 00:00:05 Section 2: 00:25:30 Section 3: 00:56:00 PuppyJusticeAutomated videos are created by a program written by Adam Schwalm. This program is available on github here: https://github.com/ALSchwalm/PuppyJusticeAutomated The audio and transcript used in this video is provided by the Chicago-Kent College of Law under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License. See this link for details: https://creativecommons.org/licenses/by-nc/4.0/
Просмотров: 247 PuppyJusticeAutomated
Actavis CEO on Allergan | Mad Money | CNBC
 
07:02
One of the best performing stocks in the market this year is at the center of an authentic Wall Street takeover war. Could it give your portfolio the lift it needs? » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Get the latest news: http://www.cnbc.com Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Actavis CEO on Allergan | Mad Money | CNBC
Просмотров: 11675 CNBC
New Generic Adderall! Be aware
 
02:48
There is a new generic Adderall floating around pharmacies. The capsule is a blue capsule that allegedly has different ingredients from Teva brand. I have tried it out but it's not working for me. I may be going back to Vyvanse.
Просмотров: 9214 MarionF
Actavis to Purchase Forest Labs in $25B Pharma Deal
 
03:57
Feb. 18 (Bloomberg) -- Bloomberg News' Cristina Alesci reports on the $25 billion deal for Forest labs by Actavis to increase its focus on branded medicine on Bloomberg Television's "Bloomberg Surveillance." -- Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg Bloomberg Television offers extensive coverage and analysis of international business news and stories of global importance. It is available in more than 310 million households worldwide and reaches the most affluent and influential viewers in terms of household income, asset value and education levels. With production hubs in London, New York and Hong Kong, the network provides 24-hour continuous coverage of the people, companies and ideas that move the markets.
Просмотров: 5019 Bloomberg
Pharmacology II - Generics Act
 
05:47
Просмотров: 128 Lotes Joy Sabuquia
Perrigo Company CEO: A Generic Grower | Mad Money | CNBC
 
06:08
This generic drug giant stock has taken a beating so far this year. Is it prime to snap this one up or is there a healthier option? » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Get the latest news: http://www.cnbc.com Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Perrigo Company CEO: A Generic Grower | Mad Money | CNBC
Просмотров: 3592 CNBC
Bristows' Life Sciences Seminar:  Competition law in the pharmaceutical industry
 
01:10:32
The application of competition law to the pharma sector has undergone a significant evolution over the last few years. Companies in the pharmaceutical industry need to understand how competition law applies to many of their everyday activities from filing for patents, distributing and marketing their products and settling disputes. Drawing on the most recent cases and developments at EU level and in the Member States, Bristows’ experts will provide a practical update on how to navigate what can sometimes appear to be a grey area. The recently published Lundbeck and Servier decisions will be a particular focus of interest in the discussion of patent settlement agreements and related areas. Speakers: Pat Treacy and Sophie Lawrance
Просмотров: 468 Bristows Law Firm
Watson Pharmaceuticals Celebrates Rebranding with Name and Symbol Change
 
00:57
Executives and guests of Watson Pharmaceuticals, Inc., will visit the New York Stock Exchange to celebrate its new global name — Actavis — and a multi-year rebranding, including a new ticker symbol. To mark the occasion, Paul Bisaro, President and CEO of Watson, and members of Watson's executive leadership team will ring the NYSE Closing Bell. About Watson Pharmaceuticals, Inc. (NYSE: WPI) Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. Watson is the world's third-largest generics manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Watson's global branded pharmaceutical business develops and markets products principally in Urology and Women's Health, and is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories. In addition, Watson is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business. Watson has announced that it will adopt a new global name -- Actavis -- effective in 2013.
Просмотров: 2099 New York Stock Exchange
What is a Generic Drug?
 
02:49
http://generic-drug-pharmacy.com Understanding generic drugs with clear explanation by a doctor. Using genenics with the same quality and effect as brand name but save your money. Ask your doctor in order try generic medication whenever possible.
Просмотров: 638 genericdrugsonline
Pharmaceutical News: Actavis to achieve record revenues in 2012
 
04:13
Actavis positioned to achieve record revenues in 2012 and grow faster than the European generics industry For the first time ever in the history of Actavis, the Company aims to achieve record revenues of EUR 2bn this year, an all-time high. "We targeted this figure in our 2012 budget and are confident of achieving our goal. With revenues of EUR 1.6bn after nine months, we are right on track," asserts CEO Claudio Albrecht, taking stock of Actavis' positive performance during the first three quarters of the year. Employing the concept of "Think Smart Medicine", the Austrian manager (53) has successfully repositioned Actavis to face the challenges of the generics industry head on. "We took over the helm at Actavis in a very difficult situation and managed to turn the Company around much quicker than expected. Now we are proud to hand over a healthy and fast-growing company with extraordinary, well trained and talented people."
Просмотров: 1744 Wirtschaftsvideo
Generic Awareness by Endless Thoughts
 
01:17
This video is about generic medicines what is generic medicines? why it is not that costly?
Просмотров: 67 Endless Thoughts
Actavis - 60 years in the pharmaceutical industry in Dupnitza
 
01:58
proTechnica EVENT: Light, sound, multimedia, truss Client: Re:quest Date: 01.08.2014 Place: Dupnitza
Просмотров: 173 proTechnicaEVENT
Webinar : Hot Topics in Generic Drug Entry and Regulation
 
46:19
Hot Topics in Generic Drug Entry and Regulation -- Examining Recent Trends in Citizens Petitions , "Pay for Delay " Settlements and Strategies for Navigating the Delicate Intersection of IP and Regulatory Law Presented by Chad A. Landmon Partner Axinn, Veltrop & Harkrider LLP Examining the causes and effects of the recent uptick in citizens petitions Understanding the ever-changing review requirements Obtaining approval in light of pending citizens petitions Strategies for obtaining court review of petition decisions Update on the current status of recent trends in "pay-for-delay" settlements and the fallout from FTC v. Actavis Chad Landmon is a partner at Axinn, Veltrop & Harkrider LLP, where he chairs the FDA Practice Group and co-chairs the IP Group. Mr. Landmon has extensive experience in food and drug law and patent litigation and counseling. His patent litigation practice is national in scope and concentrates on the life sciences industry. Mr. Landmon maintains a particular focus on Paragraph IV litigation. Mr. Landmon provides counseling and litigation services relating to patent, FDA and antitrust issues involving the development and marketing of new and generic drug products. He has litigated a wide variety of Paragraph IV cases in numerous jurisdictions, including cases involving blockbuster drugs. His FDA matters involve petitioning FDA and litigating issues relating to the Hatch-Waxman Act, including marketing exclusivities, patent listing, certification and notification requirements, bioequivalence, labeling and other issues relevant to the FDA drug approval process. Mr. Landmon's practice also includes matters involving the intersection of the antitrust and patent laws, such as issues arising from the settlement of patent and Hatch-Waxman exclusivity disputes. Mr. Landmon frequently speaks and writes about issues relating to the Hatch-Waxman Act and pharmaceutical patent litigation.hatch
Просмотров: 1689 Matt Godson
Actavis - Twice As
 
02:08
This brand film was produced for the day one launch of the merged Watson Pharmaceutical + Actavis global enterprise creating the 3rd largest generic drug company in the world. The Tribe production was soup-to-nuts: discovery-strategy, scripting, shooting all original footage in three US facilities, one in Europe and one in India, and complete post-production here in Chatham (editing, music, voice-over casting, recording narrator, etc). We simultaneously produced an internal employee video for 17,000 employees worldwide to help reinforce the new culture.
Просмотров: 1298 Tribe Pictures
Courts weigh in on generic drug delays
 
11:22
Are less-expensive generic drugs being delayed to market by so-called "pay for delay" deals between drug companies? That's the allegation of the Federal Trade Commission, which has made fighting the deals one of its top priorities. NewsHour Weekend correspondent Megan Thompson spoke to Ed Silverman who writes the Pharmalot Blog for the Wall Street Journal, and has covered the pharmaceutical industry for almost 20 years.
Просмотров: 800 PBS NewsHour
Actavis CEO Brent Saunders | Mad Money | CNBC
 
08:00
The man behind the biggest pharma deal in recent history discusses what the Allergan acquisition could do for the stock. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about Actavis here: http://www.cnbc.com/id/102513480 "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Read the latest news: http://madmoney.cnbc.com Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Visit CNBC.com: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Actavis PLC CEO Brent Saunders | Mad Money | CNBC
Просмотров: 2819 CNBC
How to Buy Prescription Drugs in Mexico without a Prescription
 
08:23
As a full time RVer, medical insurance and prescription management can be challenging. Recently I ran out of my migraine medicine so took a trip to Mexico to buy my meds over the counter. This video shows how to buy prescription drugs in Mexico and answers questions about what can and can NOT be bought. Watch and join me as I visit Mexico with my friend Bob to stock up on prescription medicine.
Просмотров: 137278 Carolyn's RV Life
Teva to Buy Allergan Generic Drug Business for $40.5 Billion
 
01:05
Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. The acquisition should help Israel-based Teva, already the world's largest generic drugmaker, boost growth at a time its top drug, multiple sclerosis treatment Coxaprone, is facing competition. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and because Allergan is strong in so-called biosimilar drugs. Teva's shares jumped 10.6 percent in Tel Aviv after the deal was announced. Teva said in a statement it will pay $33.75 billion in cash and shares of Teva valued at $6.75 billion, representing a 10 percent stake in the Israel-based company. http://feeds.reuters.com/~r/reuters/topNews/~3/LD_PPr1Xq0M/story01.htm http://www.wochit.com This video was produced by Wochit using http://wochit.com
Просмотров: 749 Wochit Business
Generic medicines and drugs
 
01:01
Generic drugs are drugs and medicines, which is equivalent to the branded products in dose, strength, route of administration, quality, performance and intended use. It can also term refers to any type of drug marketed under the chemical name without advertising, or the chemical composition of the drug instead of the brand under which the drug is selling the name. Although it can not be associated with a particular company, the drugs are often subject to government regulations in the countries in which they are dispensed with. It is labeled with the manufacturer's name and generic name does not have the name of the United States or the international common name for the drug approved. #Generic medicines and drugs
Просмотров: 21 suman gupta
'I took my napkin, and off we went': Robert Wessman's billion dollar vision | World Finance
 
03:34
In June 2009, Robert Wessman – former CEO of multi-billion dollar pharmaceuticals business Actavis – met with investors in a New York restaurant to discuss his vision for a new pharma business model: Alvogen. He explains how he grabbed a napkin to sketch out his ideas – a napkin he still has to this day, and brings out every couple of years. This year the company has surpassed the $1bn sales target he set himself eight years ago. Watch our other interviews with the Alvogen chairman and CEO, where he discusses his vision of leadership, and the pressures in the generic pharmaceuticals market today. For a full transcript visit: https://www.worldfinance.com/videos/i-took-my-napkin-and-off-we-went-robert-wessmans-billion-dollar-vision For more World Finance videos go to https://www.worldfinance.com/videos/
Просмотров: 12094 worldfinancevideos
FTC v. Actavis discussion (2013)
 
01:24:20
In PIJIP's ongoing Supreme Court series, counsel for parties and amici will discuss intellectual property cases on the afternoon of oral argument, addressing the reaction of the Court at oral argument. In this case the Supreme Court examines whether reverse-payment agreements are per se lawful unless the underlying patent litigation was a sham or the patent was obtained by fraud (as the court below held), or instead are presumptively anticompetitive and unlawful (as the Third Circuit has held). Reverse payment agreements are a type of settlement agreement where brand-name drug manufacturers pay potential generic competitors to agree not to sell competing generic drugs for a period of years. http://www.pijip-impact.org/events/ftc-v-watson/ --- Panel: Michael Carroll -- Washington College of Law, Moderator Julia York -- Skadden, Arps, Slate, Meagher & Flom LLP, counsel for Respondent, Actavis, Inc. Rohit Singla-- Munger, Tolles & Olson LLP, counsel for Respondent, Solvay Pharmaceuticals, Inc. Ryan Christian -- White & Case LLP, counsel for Respondent, Par Pharmaceutical Companies, Inc. Krista Cox -- Knowledge Ecology International, counsel for amicus Knowledge Ecology International, supporting Petitioner Scott Hemphill -- Columbia Law School
Просмотров: 818 pijipvideo
Pharmaceutical deals
 
02:40
A few big deals are being done -- Actavis buying Warner Chilcott, and Valeant purchasing Bausch & Lomb - but is this the start of another bout of industry consolidation or just more defensive moves? Lex's Julia Grindell and Vincent Boland discuss. For more video content from the Financial Times, visit http://www.FT.com/video
Просмотров: 363 Financial Times
Highlights of GPhA 2013: CEOs Unplugged
 
01:25:00
Discussion featuring Donald DeGolyer, President, Sandoz, Inc.; Tony Mauro, President, Mylan North America; Thomas Moore, President, Hospira, Inc.; Allan Oberman, President & CEO, Teva Americas Generics and Siggi Olafsson, President, Actavis Pharma. Discussion moderated by Ronny Gal, Ph.D., Senior Analyst, Sanford C. Bernstein & Co. and Randall Stanicky, Managing Director, Equity Research, Specialty Pharmaceuticals, CANACCORD|Genuity
Просмотров: 546 GPhAonline
Pfizer, Allergan Create Largest Pharmaceutical Merger
 
01:44
Pfizer and Allergan are set to reach a $150 billion deal that would create the world's largest drug maker in terms of sales, according to the Wall Street Journal.
Просмотров: 944 CBN News
The best top 10 pharmaceutical companies in USA
 
00:25
Top 10 pharmaceutical companies in USA which makes best medicine, skin care products, Baby Products 1 Gilead Sciences 2 Johnson & Johnson 3 Pfizer 4 Roche 5 Novartis 6 Amgen 7 Merck & Co. 8 Sanofi 9 AbbVie 10 Actavis
Просмотров: 939 life Planner
Drug Patent Deal Could Impact Generic Competition
 
00:40
According to legal experts, A trailblazing deal between Allergan and a Native American tribe to protect the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court. This could possibly deal a blow to generic competition. On Friday, Allergan said it had transported patents on its dry eye medicine Restasis to the St. Regis Mohawk Tribe. The tribe will exclusively license the patents back to the company in exchange for payments. In the deal announcement, allergen said it believed the Restasis patents would no longer be subject to review by the U.S. Patent Trial and Appeal Board. http://feeds.reuters.com/~r/reuters/topNews/~3/aIW_JcN33dA/u-s-tribal-patent-deal-could-have-big-impact-on-generic-drug-market-idUSKCN1BM2ST http://www.wochit.com This video was produced by YT Wochit Business using http://wochit.com
Просмотров: 125 Wochit Business
Given Compelling Valuation, Jim Cramer Is Bullish on Actavis
 
02:02
Actavis' leadership has focused on launching generic drugs for patients with rare conditions – the pharmaceutical version of a niche market. Jim Cramer and Action Alerts PLUS Research Director Jack Mohr discuss why Actavis is severely undervalued and an extremely compelling healthcare investment at these levels. The company is not only a serial acquirer; it purchases great companies and makes them even better, through disciplined cost management, synergy realization and pipeline expansion. Its recent acquisition of Allergan is a true game changer, as it offers Actavis high-profile brands including Botox, Restasis and Namanda. The most exciting of these is Botox, which currently contributes $2 billion in annual sales. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 171 TheStreet: Investing Strategies
Two generic drug makers with good medicine for the bulls.  Mylan (MYL) and Supernus Pharmaceutica..
 
04:27
Two generic drug makers with good medicine for the bulls. Mylan (MYL) and Supernus Pharmaceuticals (SUPN) Stock Market Mentor http://www.stockmarketmentor.com/?utm_source=youtube&utm_medium=ytchannel&utm_campaign=youtube
Просмотров: 2667 Stock Market Mentor
Allergan CEO on $40.5 Billion Teva deal
 
04:15
Allergan CEO Brent Saunders discusses the company’s recent selloff of its generic business to Teva for $40.5 billion. Watch Ashley Webster talk about Mergers Acquisitions and Strategy on After The Bell.
Просмотров: 4848 Fox Business
Pharmacy Business Awards 2015  winner of the Innovation in Generics Award
 
00:57
Pharmacy Business Awards 2015 Winners of the Innovation in Generics Award Jonathon Wilson, Managing Director, Actavis
Просмотров: 20 AMG MEDIA
Aurobindo rallies nearly 7% on Actavis acquisition plans
 
00:59
Wwatch: "Kanhaiya Kumar's Full Speech at JNU Campus" → https://www.youtube.com/watch?v=_df-48pHzCA -~-~~-~~~-~~-~- Aurobindo Pharma rallied as much as 6.8 per cent in trade after the generics drug maker signed a binding offer agreement to acquire commercial operations of Dublin-based Actavis in seven Western European countries.
Просмотров: 103 ET NOW
FTC v. Actavis Inc.: Oral Argument - March 25, 2013
 
01:19:42
Facts: In 2000, Solvay Pharmaceuticals successy patented AndroGel, a topical gel medication. Shortly after the FDA approved the medication, generic drug
Просмотров: 17 qiana filkins
ALEX JONES dénonce la conspiration de big pharma
 
06:08
3M Pharmaceuticals Abbott Laboratories Actavis Alcon Alkaloid Alkermes Allergan Almirall Alphapharm, a wholly owned subsidiary of Merck KGaA. Altana Pharma AG, formerly part of Altana AG, part of the Nycomed Group. Amgen Amico Laboratories Anavex Life Sciences Apotex Inc. Astellas Pharma AstraZeneca Avax Technologies Axcan Pharma [edit]B-D Bargn Farmaceutici Phils Co Barr Bausch & Lomb Baxter International Bayer Schering Pharma AG Beximco Pharmaceuticals Ltd Bial Biogen Idec, merger of Biogen and Idec Pharmaceuticals. Biolex Bionovo Biotecnol Biovail Biovitrum Boehringer-Ingelheim Bosnalijek Bristol-Myers Squibb Cadila Healthcare Celgene Cephalon Chugai Pharmaceutical Co. Cipla Crucell CSL Limited Daiichi Sankyo Dainippon Sumitomo Pharma Dawakhana Shifaul Amraz Debiopharm Diabetology Ltd Dr. Reddy's Laboratories [edit]E-J Ego Pharmaceuticals Eisai (company) Élan Corporation Eli Lilly and Company Elorac, Inc. Emergent BioSolutions Eskayef Bangladesh Limited F. Hoffmann--La Roche Ltd., which owns Genentech and Chugai Pharmaceuticals Ferozsons Laboratories Ferring Pharmaceuticals Forest Laboratories Fresenius Medical Care Galapagos NV Galderma Laboratories Genentech, a subsidiary of Hoffmann-La Roche Genzyme Goodwin Biotechnology Gulf Pharmaceutical Industries (Julphar) Getz Pharma Gilead Sciences GlaxoSmithKline GPC Biotech Hetero Drugs Hexal Australia Hikma Pharmaceuticals Hoffmann--La Roche Hospira IMULAN BioTherapeutics, LLC Institute for OneWorld Health Intas Biopharmaceuticals Intercytex Janssen Pharmaceutica Products, a subsidiary of Johnson & Johnson Jenapharm, a subsidiary of Bayer Schering Pharma JN-International Medical Corporation Johnson & Johnson [edit]K-L King Pharmaceuticals Krka, d. d. Kyowa Hakko Lundbeck Lupin Laboratories [edit]M Melior Discovery Menarini Merck & Co. Merck KGaA Mitsubishi Pharma Mylan [edit]N Nectar Lifesciences Novartis Novo Nordisk Nycomed [edit]O Orion Pharma Ortho-McNeil Pharmaceutical, a subsidiary of Johnson & Johnson Otsuka Pharmaceutical Co. [edit]P Panacea Biotec Ltd Par Pharmaceutical Perrigo Pfizer Pharmacosmos Pharma Nord Pierre Fabre Group Piramal Healthcare Pliva Procter & Gamble Purdue Pharma [edit]R Ranbaxy Laboratories, generics arm of Daiichi Sankyo Renovo Respa Pharmaceuticals Rubicon Research [edit]S Sanofi-Aventis Schering-Plough Sepracor Servier Laboratories Shionogi Shire plc Sigma Pharmaceuticals Sinopharm Group Solvay Group Square Pharmaceuticals Ltd. Bangladesh STADA Arzneimittel Strides Arcolab Sun Pharmaceutical [edit]T Taiho Pharmaceutical Takeda Pharmaceutical Company TAP Pharmaceutical Products, a joint-venture of Abbott and Takeda. Temmler Teva Pharmaceutical Industries Torrent Pharmaceuticals [edit]U-Z UCB UNILAB, also known as United Laboratories Valeant Pharmaceuticals International, formerly ICN Pharmaceuticals. Vertex Pharmaceuticals Vion Pharmaceuticals, Inc. ViroPharma Warner Chilcott Watson Pharmaceuticals Wockhardt Wyeth, a subsidiary of Pfizer Zandu Pharmaceuticals Zentiva
Просмотров: 1162 XSS18X
Addiction
 
05:42
What causes addiction? Easy, right? Drugs cause addiction. But maybe it is not that simple. This video is adapted from Johann Hari's New York Times best-selling book 'Chasing The Scream: The First and Last Days of the War on Drugs.' For more information, and to take a quiz to see what you know about addiction, go to www.chasingthescream.com Support us on Patreon so we can make more stuff: https://www.patreon.com/Kurzgesagt?ty=h Get the music of the video here: https://soundcloud.com/epicmountain/addiction https://epicmountainmusic.bandcamp.com/track/addiction An interactive version of this video: http://www.addiction.mobydigg.de (works on mobile) Or follow us on social media or reddit: http://kurzgesagt.org https://www.reddit.com/r/kurzgesagt https://www.facebook.com/Kurzgesagt https://twitter.com/Kurz_Gesagt THANKS A LOT TO OUR LOVELY PATRONS FOR SUPPORTING US: T0T0S, Ryan OHoro, Matthieu de Canteloube, Vince, Thomas Shiels, Brian David Henderson, Jim Yang, Arnav Guleria, Clemens, Tahseen Mushtaque, Jochen, Vahur S, Harry, BurmansHealthShop, Nils Caspar, Holger Fassel, Jackson R Hanna, Pascal de Reuck, ByeongWook Lee, Guus Ketelings, Franko Papić, Thalia, Narat, Suchartsunthorn, Lorenz Zahn, Brian Aparicio, Jörg Vogelsang, Rashed Ali, Darwin Ranzone, Tyler Thornton, David Pfister, Han Saini, Ute Moll, Ioanna Bischinioti, Jenny Zhou, Vince Babbra. Avi Yashchin, Dan Cortes, Matt K, Phiroze Dalal, Marcelo Fernandes de Souza Filho, A La Mode, Tom Wardrop, Shawn Marincas, Pontus Attåsen, Paul, Marc Dumont, Robert McKone, Todd Binkley, Matthew von der Ahe, Thomas Russell, Erick, Vivek Kotecha, Artur Szczypta, Jeff Fellows, Daniel Duffee, Konstantin Shabashov, Tim drake, Mike Galles, Evgenia Yigitalieva, Vrm Vee Are Em, Timothy Noble Everything We Think We Know About Addiction Is Wrong Help us caption & translate this video! http://www.youtube.com/timedtext_cs_panel?c=UCsXVk37bltHxD1rDPwtNM8Q&tab=2
Просмотров: 18279330 Kurzgesagt – In a Nutshell
2nd Congress Of The South East Europe GP/ Family Doctors Association
 
03:06
Actavis argues in favour of generic drugs in South East European countries. About 150 doctors from Bulgaria and neighbouring countries were participating the congress in Plovdiv/Bulgaria. . One central theme was the use of generic drugs in South East European countries. Especially in Serbia, Romania and Bulgaria many people are not being treated. In this case generic pharmaceuticals can add strong benefits.
Просмотров: 62 P8 Marketing
Hebbuli  {Generic medicine}.
 
01:57
This scene is taken from movie "HEBBULI" and it is related to Generic medicine. ☺️☺️☺️☺️☺️☺️☺️☺️☺️.
Просмотров: 243 Ashutosh Vimal
In Business- Aurobindo To Buyout Actavis' EU Ops
 
00:44
Aurobindo Pharma has inked a deal to buy Actavis' generic operations in seven Western European countries. Aurobindo will pay $41 million for the Dublin-based drug maker's generic products, marketing authorizations and license rights in countries including France and Italy. Bloomberg TV India's Agam Vakil shares a detailed report. www.btvin.com
Просмотров: 113 Bloomberg TV India
Round Table -2: Pharma Shippers Forum
 
01:16:29
http://stattimes.com - Enno Osinga, SVP, Cargo, Amsterdam Airport Schiphol & Vice Chairman, TIACA moderates a round table discussion on the challenges and special needs of the pharma sector that depends on air cargo to move goods across the world. The forum saw participation of representatives of leading pharmaceutical companies in India. Venugopal G Somani, Joint Drugs Controller (India); Ryan Viegas, VP, Supply Chain & Procurement, Watson Pharma (Actavis); Raghuveer Gopalakrishna Kini, Executive Director, Pharmaceuticals Export Promotion Council of India (PHARMEXCIL); Nanne Onland, MD, Cargonaut; Deepak Kotak, Head, Life Science & Healthcare/Chemical, DHL Logistics and Radharamanan Panicker, CEO, Cargo Service Center share their thoughts and ideas during the session.
Просмотров: 642 STAT Media
Actavis Video Animasyon
 
01:35
Created by Amil Toprak
Просмотров: 265 conradpasa
Watson Pharmaceuticals
 
13:16
Просмотров: 1885 Thinking Cap Media Company
Fetty Wap "679" feat. Remy Boyz [Official Video]
 
03:44
The official Fetty Wap "679" music video featuring Remy Boyz. Record produced by Peoples. Download "679" http://flyt.it/679 Stream "Bruce Wayne" the mixtape OUT NOW: https://ffm.to/brucewayne Download Fetty Wap's "Trap Queen" single here: http://flyt.it/TrapQueen ►Website: http://www.fettywap.com/ ►Instagram: https://instagram.com/FettyWap1738/ ►Twitter: https://twitter.com/fettywap ►Facebook: https://www.facebook.com/pages/Fetty-Wap/398037297030118
Просмотров: 335044780 Harlem Fetty
Africa Drug Patents
 
03:53
The South African government is close to passing new laws about intellectual property including drug patents. Health activists say that could allow people to buy cheaper, generic medicines. But as Emilie Iob reports, a fight may be brewing over the move.
Просмотров: 172 TV2Africa
Pfizer Loses Drug Patent Fight In UK Top Court
 
00:41
According to Reuters, Pfizer lost the final round in a lengthy patent battle in Britain, after the country’s highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica. The Supreme Court decision is a blow for the U.S. drugmaker — which had sought to affirm a secondary medical use patent for the product. Lyrica was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain. However, the Supreme Court ruled that the secondary patent claims relevant to neuropathic pain were invalid. http://feeds.reuters.com/~r/reuters/topNews/~3/uoDkws1Eg4M/pfizer-loses-drug-patent-fight-in-uk-top-court-may-face-claims-idUSKCN1NJ19S http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Просмотров: 55 Wochit News
Israel-Based Teva Pharmaceutical Industries Smacks Down With Mylan With $40B Bid
 
01:13
As Israel's Teva Pharmaceutical Industries (TEVA) unveiled its $82 per share bid for Mylan (MYL) Tuesday, the hostile takeover attempt may be a harbinger of things to come. As consolidation increases in the generics pharmaceutical area, it may leave very few companies standing as potential targets. Mylan already has an outstanding $29 billion offer for Perrigo (PRGO). Other big consolidators in the sector besides Teva include Actavis (ACT), Forest Laboratories (FRX) and Abbott Laboratories (ABT), The Deal's Laura Cooper reports. But as the deal field narrows and bigger deals are announced, they are also likely to draw the attention of regulators. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 2656 TheStreet: Investing Strategies
Analyst Says Actavis' $25 Billion Purchase of Forest Labs is Smart
 
01:49
Drugmaker Actavis said on Tuesday that it will buy Forest Laboratories for approximately $25 billion. The deal stands to give Actavis a broader portfolio of pharmaceuticals, which would enable the combined company to sell more products to doctors and hospitals, according to James Molloy, Managing Director at Janney Montgomery Scott. Molloy explains why he believes the deal is a smart one for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 740 TheStreet: Investing Strategies